Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - AccuredShares IssuedShares OutstandingShares Outstanding
Ratios

Zentalis Pharmaceuticals (ZNTL) Shares Outstanding (2021 - 2026)

Zentalis Pharmaceuticals has reported Shares Outstanding over the past 6 years, most recently at $71.2 million for Q1 2026.

  • For Q1 2026, Shares Outstanding fell 1.1% year-over-year to $71.2 million; the TTM value through Mar 2026 reached $71.2 million, down 1.1%, while the annual FY2025 figure was $69.1 million, 3.08% down from the prior year.
  • Shares Outstanding for Q1 2026 was $71.2 million at Zentalis Pharmaceuticals, up from $69.1 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $72.2 million in Q3 2025 and troughed at $45.6 million in Q1 2022.
  • A 5-year average of $66.6 million and a median of $70.8 million in 2023 define the central range for Shares Outstanding.
  • Biggest five-year swings in Shares Outstanding: surged 30.4% in 2023 and later decreased 3.08% in 2025.
  • Year by year, Shares Outstanding stood at $59.3 million in 2022, then rose by 19.38% to $70.8 million in 2023, then increased by 0.73% to $71.3 million in 2024, then dropped by 3.08% to $69.1 million in 2025, then grew by 3.0% to $71.2 million in 2026.
  • Business Quant data shows Shares Outstanding for ZNTL at $71.2 million in Q1 2026, $69.1 million in Q4 2025, and $72.2 million in Q3 2025.